Preclinical data on the vaccine candidate show that ALZ-101 has a long-lasting effect and that antibodies can be observed even six months after the last dose. Antibodies increase sharply after refill doses of the vaccine, suggesting that an immunological memory has been created by the immunization. In addition, antibodies can be observed in spinal fluid, suggesting that they reach the central nervous system in expected amounts. The vaccine thus appears to be effective even as a long-term (chronic) treatment. The poster also shows base line disease characteristics on all patients included in the ongoing phase 1b clinical trial. The conclusion is that ALZ-101 stimulates the production of antibodies for a long time, and that these can reach the brain in relevant amounts.

AD/PD™ - International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders - is an international conference on neurodegenerative diseases held in Gothenburg, Sweden, March 28 - April 1. The AD/PD™ conference has become an important scientific forum and event in the field of neurodegenerative diseases, attracting leading medical and scientific experts from around the world. Alzinova is there to network and present the Company's drug projects to Key Opinion Leaders, potential licensees and partners. In connection with the conference, Alzinova's Chief Scientific Officer Anders Sandberg will present a scientific poster summarizing preclinical data for the Company's vaccine candidate ALZ-101.

The poster will be available on Alzinova’s website after the presentation.